DPHIL MA - Traws Pharma Executive Chairman

TRAW Stock   5.02  0.31  5.82%   

Chairman

DPHIL MA is Executive Chairman of Traws Pharma
Age 66
Address 12 Penns Trail, Newtown, PA, United States, 18940
Phone267 759 3680
Webhttps://www.trawspharma.com

Traws Pharma Management Efficiency

The company has return on total asset (ROA) of (0.5251) % which means that it has lost $0.5251 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.9652) %, meaning that it created substantial loss on money invested by shareholders. Traws Pharma's management efficiency ratios could be used to measure how well Traws Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.88 in 2024. Return On Capital Employed is likely to climb to -1.43 in 2024. At this time, Traws Pharma's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 1.9 M in 2024, whereas Non Currrent Assets Other are likely to drop 855.00 in 2024.

Similar Executives

Found 3 records

CHAIRMAN Age

Anthony HsiehLoandepot
59
Raymond StataAnalog Devices
90
Henry KeizerHertz Global Holdings
62
Traws Pharma (TRAW) is traded on NASDAQ Exchange in USA. It is located in 12 Penns Trail, Newtown, PA, United States, 18940 and employs 17 people. Traws Pharma was previously known as Onconova Therapeutics and was traded on NASDAQ Exchange under the symbol ONTX. Traws Pharma is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Traws Pharma Leadership Team

Elected by the shareholders, the Traws Pharma's board of directors comprises two types of representatives: Traws Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Traws. The board's role is to monitor Traws Pharma's management team and ensure that shareholders' interests are well served. Traws Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Traws Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert MD, Acting Officer
DPHIL MA, Executive Chairman
Mark CPA, Chief Officer
Victor MD, Chief Oncology
Steven MD, President Oncology
Nikolay Savchuk, COO Director
Charles Pauza, Chief Virology
Werner Cautreels, CEO Director
C Pauza, Chief Virology

Traws Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Traws Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Traws Stock Analysis

When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.